Filing Details
- Accession Number:
- 0001179110-12-015259
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-10-17 18:27:34
- Reporting Period:
- 2012-10-16
- Filing Date:
- 2012-10-17
- Accepted Time:
- 2012-10-17 18:27:34
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1012140 | Onyx Pharmaceuticals Inc | ONXX | Biological Products, (No Disgnostic Substances) (2836) | 943154463 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1197018 | Anthony N Coles | C/O Onyx Pharmaceuticals, Inc. 249 E. Grand Ave. South San Francisco CA 94080 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-10-16 | 86,224 | $29.03 | 194,567 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2012-10-16 | 39,375 | $35.18 | 233,942 | No | 4 | M | Direct | |
Common Stock | Disposition | 2012-10-16 | 125,599 | $0.00 | 108,343 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2012-10-16 | 86,224 | $0.00 | 86,224 | $29.03 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2012-10-16 | 39,375 | $0.00 | 39,375 | $35.18 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
13,776 | 2018-03-31 | No | 4 | M | Direct | |
65,625 | 2021-03-31 | No | 4 | M | Direct |
Footnotes
- Shares sold pursuant to a 10b5-1 Plan.
- The shares were sold at prices ranging from $90.00 to $90.03. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- Fully vested.
- 12.5% of the shares subject to the option became exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.